JBCHEPHARM — J B Chemicals and Pharmaceuticals Income Statement
0.000.00%
- IN₹265.18bn
- IN₹260.96bn
- IN₹39.18bn
- 100
- 14
- 73
- 71
Annual income statement for J B Chemicals and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20,425 | 24,242 | 31,493 | 34,842 | 39,180 |
| Cost of Revenue | |||||
| Gross Profit | 12,625 | 14,894 | 18,729 | 21,932 | 24,937 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 15,550 | 19,496 | 25,569 | 27,298 | 30,579 |
| Operating Profit | 4,875 | 4,746 | 5,924 | 7,544 | 8,601 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 5,969 | 5,049 | 5,552 | 7,515 | 8,874 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4,485 | 3,860 | 4,100 | 5,526 | 6,596 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 4,480 | 3,854 | 4,098 | 5,526 | 6,596 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4,480 | 3,854 | 4,098 | 5,526 | 6,596 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 26.4 | 24.8 | 26.2 | 34.9 | 41.6 |
| Dividends per Share |